On October 2, 2002 Cancer Research UK reported its new technology transfer company with a remit to exploit the fruits of its world class research programme into preventative strategies, diagnostic kits and new therapies for the benefit of cancer patients (Press release, Cancer Research Technology, OCT 2, 2002, View Source [SID1234523468]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cancer Research Technology (CRT) is formed through the merger of Cancer Research Ventures (CRV) and Imperial Cancer Research Technology (ICRT), the respective technology transfer companies of the Cancer Research Campaign and the Imperial Cancer Research Fund who themselves merged on February 4, 2002, to become Cancer Research UK.
Harpal Kumar has been appointed as Chief Executive. David Newbigging, Deputy Chairman of the Council of Cancer Research UK, has been appointed non-executive Chairman and it is intended that Melanie Lee, who is a non-executive Director of CRT and Research and Development Director of Celltech plc, will succeed him in due course